MOLBIO DIAGNOSTICS LTD (MOLBIO) financials
MOLBIO DIAGNOSTICS LTD (MOLBIO) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.
Molbio Diagnostics is an innovative point-of-care (POC) diagnostics company that develops affordable, rapid, and accurate diagnostic solutions for infectious and non-communicable diseases. Its flagship product, Truenat, is a portable, battery-powered PCR testing platform that delivers results withinan hour. Designed for use in resource-limited settings, it enables quick and decentralised disease…
- Market Cap: ₹17,198Cr.
- Current Price: ₹1,492
- Stock P/E: 199
- ROE: 13.8%
- ROCE: 18.0%
- Book Value: ₹123
- Dividend Yield: 0.00%
- 52W High / Low: ₹1,687/926
In Sep 2026, MOLBIO DIAGNOSTICS LTD (MOLBIO) reported sales ₹249 Cr and net profit ₹31 Cr.
Annual Mar 2026: sales ₹1,313 Cr, net profit ₹145 Cr.
Shareholding: Promoters 41.29% (Sep 2026), FIIs 1.59% (Sep 2026), DIIs 19.09% (Sep 2026), Public 38.04% (Sep 2026), No. of Shareholders 50,395% (Sep 2026).
| Category | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|
| Sales | 95 | 579 | 439 | 399 | 249 |
| YoY Sales growth | — | — | — | +319% | -57% |
| Expenses | 105 | 445 | 332 | 308 | 190 |
| Operating Profit | -10 | 134 | 107 | 92 | 59 |
| OPM % | -10% | 23% | 24% | 23% | 24% |
| Other Income | 1 | 2 | 3 | 1 | 4 |
| Interest | 2 | 4 | 9 | 9 | 6 |
| Depreciation | 7 | 9 | 10 | 8 | 14 |
| Profit before tax | -17 | 123 | 91 | 76 | 42 |
| Tax % | -23% | 25% | 28% | 25% | 26% |
| Net Profit | -13 | 92 | 66 | 57 | 31 |
| EPS in Rs | -1.19 | 8.16 | 5.83 | 5.02 | 2.72 |
| Raw PDF | — | — | — | — | — |
| Category | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Sales | 1,271 | 776 | 327 | 756 | 971 | 1,313 |
| Sales growth | — | -39% | -58% | +132% | +28% | +35% |
| Expenses | 676 | 457 | 286 | 552 | 746 | 1,061 |
| Operating Profit | 595 | 319 | 40 | 204 | 226 | 252 |
| OPM % | 47% | 41% | 12% | 27% | 23% | 19% |
| Other Income | 1 | 5 | 8 | -21 | -2 | 4 |
| Interest | 35 | 25 | 6 | 8 | 9 | 23 |
| Depreciation | 12 | 42 | 19 | 24 | 26 | 36 |
| Profit before tax | 549 | 258 | 23 | 152 | 188 | 198 |
| Tax % | 25% | 27% | 32% | 27% | 26% | 27% |
| Net Profit | 410 | 187 | 16 | 111 | 140 | 145 |
| EPS in Rs | 40.58 | 16.64 | 1.38 | 9.88 | 12.40 | 12.83 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Category | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 11 | 12 |
| Reserves | 333 | 681 | 737 | 848 | 988 | 1,123 | 1,405 |
| Borrowings | 257 | 105 | 57 | 70 | 26 | 346 | 251 |
| Other Liabilities | 215 | 85 | 123 | 157 | 291 | 260 | 293 |
| Total Liabilities | 806 | 874 | 920 | 1,077 | 1,307 | 1,741 | 1,961 |
| Fixed Assets | 55 | 182 | 189 | 209 | 215 | 257 | 247 |
| CWIP | 100 | 0 | 0 | 2 | 18 | 6 | 16 |
| Investments | 9 | 9 | 54 | 54 | 95 | 317 | 318 |
| Other Assets | 643 | 683 | 676 | 813 | 980 | 1,160 | 1,381 |
| Total Assets | 806 | 874 | 920 | 1,077 | 1,307 | 1,741 | 1,961 |
| Category | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from Operating Activity | 344 | 98 | 68 | 38 | 249 | -38 |
| Cash from Investing Activity | -142 | -87 | -51 | -31 | -98 | -256 |
| Cash from Financing Activity | -192 | -20 | 31 | -24 | -17 | 292 |
| Net Cash Flow | 10 | -9 | 48 | -18 | 133 | -2 |
| Free Cash Flow | 212 | 35 | 55 | 24 | 206 | -74 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 78% | 53% | 251% | 39% | 139% | 6% |
| Category | Sep 2026 |
|---|---|
| Promoters | 41.29% |
| FIIs | 1.59% |
| DIIs | 19.09% |
| Public | 38.04% |
| No. of Shareholders | 50,395 |
| Category | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor Days | 61 | 113 | 194 | 174 | 86 | 100 |
| Inventory Days | 261 | 402 | 885 | 393 | 395 | 286 |
| Days Payable | 124 | 64 | 201 | 129 | 226 | 130 |
| Cash Conversion Cycle | 198 | 450 | 877 | 438 | 254 | 256 |
| Working Capital Days | 75 | 206 | 479 | 239 | 155 | 143 |
| ROCE % | — | 41% | 4% | 22% | 21% | 18% |
Molbio Diagnostics Ltd
₹17,198Cr.
₹1,492
₹1,687/926
199
Molbio Diagnostics is an innovative point-of-care (POC) diagnostics company that develops affordable, rapid, and accurate diagnostic solutions for infectious and non-communicable diseases. Its flagship product, Truenat, is a portable, battery-powered PCR testing platform that delivers results withinan hour. Designed for use in resource-limited settings, it enables quick and decentralised disease diagnosis at the point of care.Through its wholly owned subsidiary,Bigtec Labs, Molbio has strong researchand development capabilities focused on creating diagnostic platforms for point-of-care (POC) testing. From product development to large-scale deployment, the company aimsto improve access to reliable and affordable healthcare for everyone.[1]
Quarterly results
Profit & loss
Shareholding trend
Balance sheet
Cash flows
Key ratios
Frequently asked questions
What is the market cap of MOLBIO DIAGNOSTICS LTD (MOLBIO)?
The reported market capitalisation for MOLBIO DIAGNOSTICS LTD (MOLBIO) is ₹17,198Cr. on Fincrux. Figures may update with market data and filings.
What is the current share price of MOLBIO?
The current price shown for MOLBIO DIAGNOSTICS LTD (MOLBIO) on Fincrux is ₹1,492 with a 52-week high/low of ₹1,687/926.
What is the P/E ratio of MOLBIO DIAGNOSTICS LTD (MOLBIO)?
The stock P/E for MOLBIO DIAGNOSTICS LTD (MOLBIO) is 199 on Fincrux, with ROE at 13.8% and ROCE at 18.0%.
What were MOLBIO latest quarterly results?
For Sep 2026, MOLBIO DIAGNOSTICS LTD (MOLBIO) reported sales ₹249 Cr and net profit ₹31 Cr (figures in ₹ crore unless noted).
What are MOLBIO annual sales and net profit?
For Mar 2026, MOLBIO DIAGNOSTICS LTD (MOLBIO) shows sales of ₹1,313 Cr and net profit of ₹145 Cr on the Fincrux profit & loss statement.
Who owns MOLBIO DIAGNOSTICS LTD (MOLBIO)?
Latest shareholding for MOLBIO DIAGNOSTICS LTD (MOLBIO) on Fincrux: Promoters 41.29% (Sep 2026), FIIs 1.59% (Sep 2026), DIIs 19.09% (Sep 2026), Public 38.04% (Sep 2026), No. of Shareholders 50,395% (Sep 2026).
Where can I find MOLBIO DIAGNOSTICS LTD (MOLBIO) financials?
MOLBIO DIAGNOSTICS LTD (MOLBIO) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.
Does Fincrux show MOLBIO balance sheet and cash flow?
Yes. The MOLBIO DIAGNOSTICS LTD (MOLBIO) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.